Increased expression of discoidin domain receptor 2 (DDR2): a novel independent prognostic marker of worse outcome in breast cancer patients

2013 ◽  
Vol 30 (1) ◽  
Author(s):  
Tingting Ren ◽  
Jian Zhang ◽  
Jing Zhang ◽  
Xinping Liu ◽  
Libo Yao
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Breast Cancer Patients ◽  
Discoidin Domain Receptor ◽  
Independent Prognostic Marker ◽  
Discoidin Domain Receptor 2

P13 DNA methylation in serum of breast cancer patients: An independent prognostic marker

2004 ◽  
Vol 2 (1) ◽  
pp. 44
Author(s):  
H. Fiegl ◽  
H.M. Mueller ◽  
A. Widschwendter ◽  
L. Ivarsson ◽  
G. Goebel ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Breast Cancer Patients ◽  
Independent Prognostic Marker

scholarly journals KCNJ3 is a new independent prognostic marker for estrogen receptor positive breast cancer patients

Oncotarget ◽  
2016 ◽  
Vol 7 (51) ◽  
pp. 84705-84717 ◽  
Author(s):  
Sarah Kammerer ◽  
Armin Sokolowski ◽  
Hubert Hackl ◽  
Dieter Platzer ◽  
Stephan Wenzel Jahn ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptor ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Breast Cancer Patients ◽  
Independent Prognostic Marker ◽  
Estrogen Receptor Positive ◽  
Positive Breast Cancer

p53 as an Independent Prognostic Marker in Lymph Node-Negative Breast Cancer Patients

1993 ◽  
Vol 85 (12) ◽  
pp. 965-970 ◽  
Author(s):  
R. Silvestrini ◽  
E. Benini ◽  
M. G. Daidone ◽  
S. Veneroni ◽  
P. Boracchi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Independent Prognostic Marker ◽  
Node Negative Breast Cancer

scholarly journals Clinical impact of PTEN methylation status as a prognostic marker for breast cancer

2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Amal Ramadan ◽  
Maha Hashim ◽  
Amr Abouzid ◽  
Menha Swellam
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Tumor Markers ◽  
Prognostic Marker ◽  
Methylation Status ◽  
Clinical Impact ◽  
Breast Cancer Patients ◽  
Duct Carcinoma ◽  
Cancer Group ◽  
And Control

Abstract Background Aberrant DNA methylation of phosphatase and tensin homolog (PTEN) gene has been found in many cancers. The object of this study was to evaluate the clinical impact of PTEN methylation as a prognostic marker in breast cancer. The study includes 153 newly diagnosed females, and they were divided according to their clinical diagnosis into breast cancer patients (n = 112) and females with benign breast lesion (n = 41). A group of healthy individuals (n = 25) were recruited as control individuals. Breast cancer patients were categorized into early stage (0–I, n = 48) and late stage (II–III, n = 64), and graded into low grade (I–II, n = 42) and high grade (III, n = 70). Their pathological types were invasive duct carcinoma (IDC) (n = 66) and duct carcinoma in situ (DCI) (n = 46). Tumor markers (CEA and CA15.3) were detected using ELISA. DNA was taken away from the blood, and the PTEN promoter methylation level was evaluated using the EpiTect Methyl II PCR method. Results The findings revealed the superiority of PTEN methylation status as a good discriminator of the cancer group from the other two groups (benign and control) with its highest AUC and increased sensitivity (96.4%) and specificity (100%) over tumor markers (50% and 84% for CEA and 49.1% and 86.4% for CA15.3), respectively. The frequency of PTEN methylation was 96.4% of breast cancer patients and none of the benign and controls showed PTEN methylation and the means of PTEN methylation (87 ± 0.6) were significantly increased in blood samples of breast cancer group as compared to both benign and control groups (25 ± 0.7 and 12.6 ± 0.3), respectively. Methylation levels of PTEN were higher in the blood of patients with ER-positive than in patients with ER-negative cancers (P = 0.007) and in HER2 positive vs. HER2 negative tumors (P = 0.001). The Kaplan-Meier analysis recognizes PTEN methylation status as a significant forecaster of bad progression-free survival (PFS) and overall survival (OS), after 40 months follow-up. Conclusions PETN methylation could be supposed as one of the epigenetic aspects influencing the breast cancer prognosis that might foretell more aggressive actions and worse results in breast cancer patients.

scholarly journals Which Cyclin E Prevails as Prognostic Marker for Breast Cancer? Results from a Retrospective Study Involving 635 Lymph Node–Negative Breast Cancer Patients

2006 ◽  
Vol 12 (11) ◽  
pp. 3319-3328 ◽  
Author(s):  
Anieta M. Sieuwerts ◽  
Maxime P. Look ◽  
Marion E. Meijer-van Gelder ◽  
Mieke Timmermans ◽  
Anita M.A.C. Trapman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Node ◽  
Retrospective Study ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Cyclin E ◽  
Breast Cancer Patients ◽  
Node Negative ◽  
Node Negative Breast Cancer

scholarly journals CD105 Expression on CD34-Negative Spindle-Shaped Stromal Cells of Primary Tumor Is an Unfavorable Prognostic Marker in Early Breast Cancer Patients

PLoS ONE ◽  
2015 ◽  
Vol 10 (3) ◽  
pp. e0121421 ◽  
Author(s):  
Leandro Marcelo Martinez ◽  
Vivian Labovsky ◽  
María de Luján Calcagno ◽  
Kevin Mauro Davies ◽  
Hernán Garcia Rivello ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Prognostic Marker ◽  
Early Breast Cancer ◽  
Stromal Cells ◽  
Primary Tumor ◽  
Breast Cancer Patients
Sign in / Sign up

Export Citation Format

Share Document